查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363066

視網膜靜脈阻塞治療的市場規模、佔有率和趨勢分析報告：按最終用戶、疾病類型、治療方法方法、地區、細分趨勢，2023-2030

Retinal Vein Occlusion Treatment Market Size, Share & Trends Analysis Report By End-user (Retail Pharmacy, Hospital & Clinics), By Disease Type (CRVO, BRVO), By Treatment (Anti-VEGF, Corticosteroid Drugs), By Region, & Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

視網膜靜脈阻塞治療市場的成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球視網膜靜脈阻塞治療市場規模將達41.8億美元，2023年至2030年年複合成長率為6.92%。

眼科疾病患病的增加、老年人口的增加、對眼科疾病治療意識的增強是推動市場成長的主要要素。現有和已通過核准產品的存在以及強大的產品平臺是預計推動市場成長的要素。此外，糖尿病和動脈粥狀硬化患病的增加可能會增加 RVO 的患病，從而對研究期間的市場產生積極影響。 RVO 新藥核准數量的增加預計將在研究期間為市場提供利潤豐厚的機會。

三星Bioepis開發了首個生物相似藥Byooviz（ranibizumab-nuna），用於治療黃斑部水腫、新生血管老齡化黃斑部病變、近視脈絡膜新生血管和RVO等視網膜疾病。 2020年9月，該藥物獲得FDA商業化核准。然而，與藥物相關的高成本可能會限制其處方並阻礙市場成長。根據《BMC 眼科》 2021 年發表的一項研究，在中國，用雷珠單抗治療中央RVO (CRVO) 和分支RVO (BRVO) 的費用約為每個品質調整生命年(QALY) 449.17 美元和454.75美元。因此，高效、安全的廉價藥物的推出預計將在預測期內為市場帶來新的成長機會。

此外，糖尿病視網膜病變、白內障、青光眼和老齡化黃斑部病變等疾病是全世界這種疾病的主要原因。老年人口的增加相應地增加了受 RVO罹患的人數。此外，生活方式的改變也增加了導致RVO的各種疾病的發生率，例如心血管疾病和高血壓。根據《刺胳針》全球衛生委員會關於全球眼健康的報告，2020年全球將有5.1億人出現未矯正的近距離視力喪失，其中5.96億人出現未矯正的近距離視力喪失，估計有100萬人患有未矯正的遠視力障礙。因此，繼發性疾病患病的增加可能會增加 RVO 的患病並支持市場成長。

視網膜靜脈阻塞治療市場報告亮點

  • 按疾病類型分類，由於研發活動和新藥開發投資的增加，以實現高效治療，分支細分市場在 2022 年佔據市場主導地位。
  • 從治療藥物來看，抗血管內皮生長因子藥物（抗VEGF藥物）由於其安全性和第一線藥物的普遍接受性，在2022年佔據最大的市場佔有率。
  • 由於藥品供應量的提高以及透過零售藥局提供的 RVO 選項等要素，零售藥局最終用戶細分市場在 2022 年佔據最大佔有率。
  • 北美地區到 2022 年將佔據 41.2% 的佔有率，確立了按地區分類的強勢地位。這是廣泛的研究和開發活動以及由於該地區政府資助增加而導致的高治療方法採用率的結果。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場動態
  • 市場促進因素
    • 視網膜疾病患病增加
    • 老年人口增加
    • 擁有強大的產品系列
  • 市場抑制因素分析
    • 對疾病缺乏認知與診斷不足
    • 治療費用高
  • 營商環境分析
    • SWOT 分析；要素因素（政治/法律、經濟/技術）
    • 波特五力分析
    • COVID-19感染疾病的影響分析

第4章 疾病業務分析

  • 視網膜靜脈阻塞治療市場：疾病類型變異分析
  • 視網膜中央靜脈阻塞（CRVO）
  • 視網膜分支靜脈阻塞症（BRVO）

第5章 業務分析（依處理方式）

  • 視網膜靜脈阻塞治療市場：治療變異分析
  • 抗血管內皮生長因子（抗VEGF）
  • 皮質類固醇藥物
  • 其他

第6章 最終使用者的業務分析

  • 視網膜靜脈阻塞治療市場：最終用戶變化分析
  • 醫院和診所
  • 零售藥房
  • 其他

第7章 區域業務分析

  • 2022年及2030年視網膜靜脈阻塞治療按地區市場佔有率
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭形勢

  • 參與企業概況
  • 財務實績
  • 參與企業
Product Code: GVR-4-68040-122-1

Retinal Vein OcclusionTreatment Market Growth & Trends:

The global retinal vein occlusion treatment market size is expected to reach USD 4.18 billion by 2030, growingat a CAGR of 6.92% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Growing prevalence of eye diseases, increasing geriatric population, coupled with rising awareness about ophthalmic disease treatment are the key factors boosting the market growth. The presence of already existing products or approved products and a strong product pipeline are factors anticipated to fuel the market growth. Furthermore, the increasing prevalence of diabetes and atherosclerosis may increase the prevalence of RVO and positively impact the market during the study period. Rising approval of novel drugs for RVO is expected to offer lucrative opportunities for the market during the study period.

Samsung Bioepis developed the first biosimilar drug Byooviz (ranibizumab-nuna) for the treatment of retinal disorders, such as macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, and RVO. In September 2020, the drug was approved by the FDA for commercialization. However, the high cost associated with drugs may limit the prescription of drugs and hinder market growth. According to a 2021 study published in BMC Ophthalmology, the treatment of central RVO(CRVO) and branch RVO (BRVO) with ranibizumab costs approximately USD 449.17 and USD 454.75 per quality-adjusted life year (QALY) in China. Therefore, the introduction of affordable drugs with high efficacy and safety is expected to create new growth opportunities for the market during the projected timeframe.

Moreover, conditions, such as diabetic retinopathy, cataract, glaucoma, and age-related macular degeneration, are major causes of the disorder globally. A rise in the elderly population is creating a proportionate increase in number of people suffering from RVO. In addition, lifestyle changes have also resulted in increased incidence of various diseases causing RVO, such as cardiovascular diseases & hypertension. According to the Lancet Global Health Commission's report on global eye health, it was estimated that in 2020, 510 million people worldwide had uncorrected close vision impairment, and 596 million people worldwide had uncorrected distance vision impairment. Thus, the increasing prevalence of secondary conditions may increase the prevalence of RVO and support market growth.

Retinal Vein Occlusion Treatment Market Report Highlights:

  • By disease type, the branch segment dominated themarket in 2022 owing to the increasing focus on R&D activities and investments to develop novel drugs for efficient treatment
  • By treatment, anti-vascular endothelial growth factor (Anti-VEGF) segment held the largest share in 2022 owing to their safety and universal acceptance as the first-line treatment option
  • The retail pharmacy end-user segment held the largest share in 2022 due to factors, such as improved accessibility of medication and available options for RVO through retail pharmacies
  • North America established a strong regional position with a 41.2% share in 2022. This is a result of the region's extensive R&D activities due to increased government funding and a high adoption rate of treatments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Disease Type and Treatment Snapshot
  • 2.3. End-user Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Increasing prevalence of retinal diseases
    • 3.4.2. Rising geriatric population
    • 3.4.3. Presence of strong product portfolio
  • 3.5. Market Restraint Analysis
    • 3.5.1. Lack of awareness and underdiagnoses of the disease
    • 3.5.2. High cost of the treatment
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Disease Type Business Analysis

  • 4.1. Retinal Vein Occlusion Treatment market: Disease Type Movement Analysis
  • 4.2. Central Retinal Vein Occlusion (CRVO)
    • 4.2.1. Central Retinal Vein Occlusion (CRVO) Market, 2018 - 2030 (USD Million)
  • 4.3. Branch Retinal Vein Occlusion (BRVO)
    • 4.3.1. Branch Retinal Vein Occlusion (BRVO) Market, 2018 - 2030 (USD Million)

Chapter 5. Treatment Business Analysis

  • 5.1. Retinal Vein Occlusion Treatment Market: Treatment Movement Analysis
  • 5.2. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
    • 5.2.1. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Market, 2018 - 2030 (USD Million)
  • 5.3. Corticosteroid Drugs
    • 5.3.1. Corticosteroid Drugs Market, 2018 - 2030 (USD Million)
  • 5.4. Others
    • 5.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-user Business Analysis

  • 6.1. Retinal Vein Occlusion Treatment Market: End-user Movement Analysis
  • 6.2. Hospital & Clinics
    • 6.2.1. Hospital & Clinics Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Retinal Vein Occlusion Treatment Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD MILLION)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. UK Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Mexico Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Reimbursement Scenario
      • 7.5.4.6. Argentina Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's overview
  • 8.2. Financial performance
  • 8.3. Participant categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Retinal Vein Occlusion Treatment market Share Analysis, 2022
    • 8.3.3. Company Profiles
      • 8.3.3.1. AbbVie Inc
      • 8.3.3.1.1. Company Overview
      • 8.3.3.1.2. Financial Performance
      • 8.3.3.1.3. Product Benchmarking
      • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. F. Hoffmann-La Roche Ltd
      • 8.3.3.2.1. Company Overview
      • 8.3.3.2.2. Financial Performance
      • 8.3.3.2.3. Product Benchmarking
      • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Regeneron Pharmaceuticals Inc
      • 8.3.3.3.1. Company Overview
      • 8.3.3.3.2. Financial Performance
      • 8.3.3.3.3. Product Benchmarking
      • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Taiwan Liposome Company, Ltd
      • 8.3.3.4.1. Company Overview
      • 8.3.3.4.2. Financial Performance
      • 8.3.3.4.3. Product Benchmarking
      • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. Aerie Pharmaceuticals Inc
      • 8.3.3.5.1. Company Overview
      • 8.3.3.5.2. Financial Performance
      • 8.3.3.5.3. Product Benchmarking
      • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. CalciMedica Inc
      • 8.3.3.6.1. Company Overview
      • 8.3.3.6.2. Financial Performance
      • 8.3.3.6.3. Product Benchmarking
      • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Outlook Therapeutics, Inc
      • 8.3.3.7.1. Company Overview
      • 8.3.3.7.2. Financial Performance
      • 8.3.3.7.3. Product Benchmarking
      • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. Kodiak Sciences Inc
      • 8.3.3.8.1. Company Overview
      • 8.3.3.8.2. Financial Performance
      • 8.3.3.8.3. Product Benchmarking
      • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. Chugai Pharmaceutical Co., Ltd
      • 8.3.3.9.1. Company Overview
      • 8.3.3.9.2. Financial Performance
      • 8.3.3.9.3. Product Benchmarking
      • 8.3.3.9.4. Strategic Initiatives
      • 8.3.3.10. Pfizer Inc
      • 8.3.3.10.1. Company Overview
      • 8.3.3.10.2. Financial Performance
      • 8.3.3.10.3. Product Benchmarking
      • 8.3.3.10.4. Strategic Initiatives
    • 8.3.4. Strategy Mapping
      • 8.3.4.1. Expansion
      • 8.3.4.2. Acquisition
      • 8.3.4.3. Collaborations
      • 8.3.4.4. Disease Type/Drug Class Launch
      • 8.3.4.5. Partnerships
      • 8.3.4.6. Others

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 3 Global Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 4 Global Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 5 Global Retinal Vein Occlusion Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 8 North America Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 9 North America Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 10 U.S. Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 12 U.S. Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 13 Canada Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 15 Canada Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 16 Europe Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 19 Europe Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 20 Germany Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 22 Germany Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 23 UK Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 24 UK Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 25 UK Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 26 France Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 27 France Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 28 France Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 29 Italy Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 31 Italy Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 32 Spain Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 34 Spain Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 35 Denmark Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 37 Denmark Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 38 Sweden Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 40 Sweden Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 41 Norway Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 43 Norway Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 48 China Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 49 China Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 50 China Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 51 Japan Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 53 Japan Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 54 India Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 55 India Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 56 India Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 57 South Korea Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 59 South Korea Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 60 Australia Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 62 Australia Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 63 Thailand Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 65 Thailand Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 66 Latin America Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 69 Latin America Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 70 Brazil Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 72 Brazil Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 73 Mexico Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 75 Mexico Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 76 Argentina Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 78 Argentina Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 83 South Africa Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 85 South Africa Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 89 UAE Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 91 UAE Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Retinal Vein Occlusion Treatment Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Retinal Vein Occlusion Treatment Market: Disease Type Movement Analysis
  • Fig. 15 Global Retinal Vein Occlusion Treatment Market, by Central Retinal Vein Occlusion (CRVO), 2018 - 2030 (USD Million)
  • Fig. 16 Global Retinal Vein Occlusion Treatment Market, by Branch Retinal Vein Occlusion (BRVO), 2018 - 2030 (USD Million)
  • Fig. 17 Global Retinal Vein Occlusion Treatment Market: Treatment Movement Analysis
  • Fig. 18 Global Retinal Vein Occlusion Treatment Market, by Anti-vascular Endothelial Growth Factor (Anti-VEGF), 2018 - 2030 (USD Million)
  • Fig. 19 Global Retinal Vein Occlusion Treatment Market, by Corticosteroid Drugs, 2018 - 2030 (USD Million)
  • Fig. 20 Global Retinal Vein Occlusion Treatment Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 21 Global Retinal Vein Occlusion Treatment Market: End-user Movement Analysis
  • Fig. 22 Global Retinal Vein Occlusion Treatment Market, by Hospital & Clinics 2018 - 2030 (USD Million)
  • Fig. 23 Global Retinal Vein Occlusion Treatment Market, by Retail Pharmacy 2018 - 2030 (USD Million)
  • Fig. 24 Global Retinal Vein Occlusion Treatment Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 25 Regional Marketplace: Key Takeaways
  • Fig. 26 Regional Outlook, 2022 & 2030
  • Fig. 27 Global Retinal Vein Occlusion Treatment Market: Region Movement Analysis
  • Fig. 28 North America Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 32 Germany Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 33 UK Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 34 France Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 42 China Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 43 India Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 44 Australia Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)